机构:[1]Department of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China[2]Department of Pathology, Tongren Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China[3]Collaborative Innovation Center of Clinical Immunology between Soochow University andSihong People’s Hospital, Sihong 223900, China[4]Department of Pathology, Sihong People’s Hospital, Sihong 223900, China[5]Laboratory Animal Research Center,Soochow University School of Medicine, Suzhou 215123, China[6]Department of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China[7]Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China苏州大学附属第二医院[8]Suzhou Key Laboratory of Tumor Microenvironment andPathology, Soochow University, Suzhou 215006, China.
Transforming growth factor-β1 (TGF-β1) acts as a tumor promoter in advanced prostate cancer (PCa). We speculated that microRNAs (miRNAs) that are inhibited by TGF-β1 might exert anti-tumor effects. To assess this, we identified several miRNAs downregulated by TGF-β1 in PCa cell lines and selected miR-3691-3p for detailed analysis as a candidate anti-oncogene miRNA. miR-3691-3p was expressed at significantly lower levels in human PCa tissue compared with paired benign prostatic hyperplasia tissue, and its expression level correlated inversely with aggressive clinical pathological features. Overexpression of miR-3691-3p in PCa cell lines inhibited proliferation, migration, and invasion, and promoted apoptosis. The miR-3691-3p target genes E2F transcription factor 3 (E2F3) and PR domain containing 1, with ZNF domain (PRDM1) were upregulated in miR-3691-3p-overexpressing PCa cells, and silencing of E2F3 or PRDM1 suppressed PCa cell proliferation, migration, and invasion. Treatment of mice bearing PCa xenografts with a miR-3691-3p agomir inhibited tumor growth and promoted tumor cell apoptosis. Consistent with the negative regulation of E2F3 and PRDM1 by miR-3691-3p, both proteins were overexpressed in clinical PCa specimens compared with noncancerous prostate tissue. Our results indicate that TGF-β1-regulated miR-3691-3p acts as an anti-oncogene in PCa by downregulating E2F3 and PRDM1. These results provide novel insights into the mechanisms by which TGF-β1 contributes to the progression of PCa.
基金:
Shanghai Changning District Committee of
Science and Technology (CNKW2016Y01), Shanghai Tongren Hospital
Project (TRYJ201501), Suzhou Science and Technology Development Program
(SYS201717), the Second Affiliated Hospital of Soochow University Advance
Research Program of the Natural Science Foundation of China Grants
(SDFEYGJ1705) ,Open project of Jiangsu State Key Laboratory of Radiation
Medicine and Projection (GJS1963) and the Priority Academic Program
Development of Jiangsu Higher Education Institutions.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类|2 区医学
小类|1 区男科学2 区泌尿学与肾脏学
最新[2025]版:
大类|2 区医学
小类|2 区男科学2 区泌尿学与肾脏学
第一作者:
第一作者机构:[1]Department of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China[2]Department of Pathology, Tongren Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China[3]Collaborative Innovation Center of Clinical Immunology between Soochow University andSihong People’s Hospital, Sihong 223900, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China[8]Suzhou Key Laboratory of Tumor Microenvironment andPathology, Soochow University, Suzhou 215006, China.
推荐引用方式(GB/T 7714):
Hu Yue-Mei,Lou Xiao-Li,Liu Bao-Zhu,et al.TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression.[J].Asian Journal Of Andrology.2020,doi:10.4103/aja.aja_60_20.
APA:
Hu Yue-Mei,Lou Xiao-Li,Liu Bao-Zhu,Sun Li,Wan Shan...&Wang Shou-Li.(2020).TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression..Asian Journal Of Andrology,,
MLA:
Hu Yue-Mei,et al."TGF-β1-regulated miR-3691-3p targets E2F3 and PRDM1 to inhibit prostate cancer progression.".Asian Journal Of Andrology .(2020)